Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the
epidermal growth factor receptor (EGFR), and both are widely used in combination with …

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

Although cancer cells are not generally controlled by normal regulatory mechanisms, tumor
growth is highly dependent on the supply of oxygen, nutrients, and host-derived regulators. It …

Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant,
human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the …

Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …

We propose a working hypothesis that integrates data from the CALGB/SWOG 80405 and
FIRE-3 studies to explain apparent discrepancies in their results. Both trials assessed the …

The clinical management of metastatic (stage IV) colorectal cancer (CRC) is a common
challenge faced by surgeons and physicians. The last decade has seen exciting …

Background KRAS wild-type mutational status is necessary but not sufficient to get benefit
from epidermal growth factor receptor inhibition. Predictive markers are currently being …

Purpose: Phase II trials in locally advanced rectal cancer have shown that cetuximab-based
neoadjuvant radiochemotherapy is feasible but without an improvement in complete …

Introduction: Magnesium plays a role in a large number of cellular metabolic reactions.
Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) …